S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
Log in

NASDAQ:TRIL - Trillium Therapeutics Stock Price, Forecast & News

$4.16
+0.42 (+11.23 %)
(As of 02/20/2020 04:00 PM ET)
Today's Range
$3.51
Now: $4.16
$4.23
50-Day Range
$1.03
MA: $3.17
$4.56
52-Week Range
$0.24
Now: $4.16
$4.86
Volume3.51 million shs
Average Volume6.42 million shs
Market Capitalization$116.64 million
P/E RatioN/A
Dividend YieldN/A
Beta2.84
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TRIL
CUSIPN/A
Phone416-595-0627

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.32) per share

Profitability

Net Income$-25,290,000.00

Miscellaneous

EmployeesN/A
Market Cap$116.64 million
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive TRIL News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter.


Trillium Therapeutics (NASDAQ:TRIL) Frequently Asked Questions

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

How were Trillium Therapeutics' earnings last quarter?

Trillium Therapeutics Inc (NASDAQ:TRIL) issued its earnings results on Friday, May, 11th. The biotechnology company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.13. View Trillium Therapeutics' Earnings History.

When is Trillium Therapeutics' next earnings date?

Trillium Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Trillium Therapeutics.

What price target have analysts set for TRIL?

2 brokers have issued 12-month target prices for Trillium Therapeutics' stock. Their forecasts range from $4.00 to $4.00. On average, they expect Trillium Therapeutics' share price to reach $4.00 in the next year. This suggests that the stock has a possible downside of 3.8%. View Analyst Price Targets for Trillium Therapeutics.

What is the consensus analysts' recommendation for Trillium Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trillium Therapeutics.

Has Trillium Therapeutics been receiving favorable news coverage?

News stories about TRIL stock have trended negative this week, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Trillium Therapeutics earned a news sentiment score of -2.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Trillium Therapeutics.

Are investors shorting Trillium Therapeutics?

Trillium Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 3,940,000 shares, an increase of 399.6% from the January 15th total of 788,700 shares. Based on an average daily trading volume, of 3,600,000 shares, the days-to-cover ratio is currently 1.1 days. Approximately 6.4% of the company's stock are sold short. View Trillium Therapeutics' Current Options Chain.

Who are some of Trillium Therapeutics' key competitors?

What other stocks do shareholders of Trillium Therapeutics own?

Who are Trillium Therapeutics' key executives?

Trillium Therapeutics' management team includes the folowing people:
  • Dr. Bjorn Johan Niclas Stiernholm, Pres, CEO & Director
  • Mr. James T. Parsons C.A., C.P.A., MAcc, CPA-CA, Chief Financial Officer (Age 54)
  • Dr. Robert Uger, Chief Scientific Officer
  • Dr. Penka Petrova, Chief Devel. Officer
  • Dr. Yaping Shou, Chief Medical Officer

Who are Trillium Therapeutics' major shareholders?

Trillium Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Jane Street Group LLC (0.10%).

Which institutional investors are buying Trillium Therapeutics stock?

TRIL stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC.

How do I buy shares of Trillium Therapeutics?

Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Trillium Therapeutics' stock price today?

One share of TRIL stock can currently be purchased for approximately $4.16.

How big of a company is Trillium Therapeutics?

Trillium Therapeutics has a market capitalization of $116.64 million. The biotechnology company earns $-25,290,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. View Additional Information About Trillium Therapeutics.

What is Trillium Therapeutics' official website?

The official website for Trillium Therapeutics is http://www.trilliumtherapeutics.com/.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at 416-595-0627 or via email at [email protected]


MarketBeat Community Rating for Trillium Therapeutics (NASDAQ TRIL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  276 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  461
MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe TRIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel